Shaping the future of diagnostics.
Today, only a handful of point-of-care tests are available for rapid detection of bacteria direct from a clinical sample. Often faulted for low sensitivity and specificity to their targets, many of these tests do not operate well because of the test sample – regardless if it is a coughed-up specimen, a few drops of blood, or urine. MicroPhage is ready to take on this pent-up demand with easy to use point-of-care tests capable of rapid direct detection.
Currently, MicroPhage is developing a portfolio of products that address the goals and needs of today's clinical diagnostics.
- Skin and Soft Tissue Infections
- Clindamycin Resistance
- Vancomycin Tolerance
- Urinary Tract Infections
- Respiratory Infections